The bayou is home to Ghostwalker Wyatt Fontenot whose powers are both deadly and necessary for his survival as part of an elite and secret para military team. But when his home and family are threatened, Wyatt becomes the most dangerous thing in the bayou. At least until a sensual and mysterious woman called Pepper enters his life, needing him in more ways then either of them were prepared for. From #1 NY Times bestselling author Christine Feehan. Find out more at http://www.ChristineFeehan.com. Paranormal romance/fantasy/thriller
Cycle for Survival, the nationwide movement to beat rare cancers, brought hundreds of supporters to Times Square on Friday for its second annual Times Square Takeover, an all-day celebration featuring high-energy stationary cycling sessions.
The day kicked off Cycle for Survival’s ninth year and the launch of registration for its 2015 events across the country.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7325451-cycle-for-survival-second-annual-times-square-takeover-2015-registration-launch/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
When a child is diagnosed with cancer, their family is presented with treatment options – often a combination of surgery, radiation and chemotherapy. Radiation and chemotherapy have been used to treat kids’ cancers for more than 50 years and often come with long-term late effects including secondary cancers, heart damage and cognitive issues. Often a child’s best chance at survival is a clinical trial which offers them the newest treatment options available.
In recognition of Childhood Cancer Awareness Month, the St. Baldrick’s Foundation will highlight the critical need to fund lifesaving research and share stories of kids affected by cancer – like Micah, who is alive today because there was a clinical trial available.
To view the multimedia release go to:
https://www.multivu.com/players/English/8284352-st-baldricks-foundation-conquer-childhood-cancers/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Critical Missions: SWAT delivers the nostalgic fast paced FPS gaming experience on your iPad, iPhone and iPod Touch devices. Enjoy the smooth and customizable touch controls and play the cross-platform first-person shooter against other players on the web and on other mobile platforms.
CRITICAL MISSIONS: SWAT KEY FEATURES
- Cross-platform 3D First-Person Shooter MMO: beat PC/Mac players and players from other mobile platforms
- Multiplayer Mode: Local network and Servers Globally (USA, Europe and Asia)
- Single Player Mode: Player vs. Customizable Bots (Terrorists, Zombies)
- Smooth and Responsive Customizable Touch Controls (--> Game menu - Settings - User Interface - Edit HUD)
- Six Game Types: Classic, Team Death Match (DTM), Zombie Mode, Zombie Match, Survival, Death Match, Juggernaut and Capture The Flag (CTF)
- Customizable settings: player HP, player speed, zombie difficulty, ect.
- Dozens of pre-installed and downloadable unique maps
Clayton, one of America’s leading builders of prefabricated homes, has released a new video featuring the story of a family whose Clayton Built® home survived the devastating Category Four Hurricane Michael.
When the hurricane made landfall Oct.10, Darla and Terry’s Clayton Built® home was along its path. The two moved to Mexico Beach, Fla. from Alabama after retirement to be closer to the beach. They originally planned to build a site built home on their newly purchased property, but after learning more about Clayton and touring the company’s Clayton SE Homes home building facility in Addison, Ala., the couple opted to purchase a Clayton Built® home from Clayton Homes of Panama City instead.
To view the multimedia release go to:
https://www.multivu.com/players/English/8335052-clayton-built-home-mexico-beach-hurricane-michael/
Did you use the plywood from your hurricane shutters to build a tree house or use your garage door brace to hold up the bird feeder? If so there’s a good chance your home may not be hurricane ready.
Being properly prepared is paramount during hurricane season. To learn more about how to protect yourself and your property, visit State Farm Learning Center. It can make a big difference to your safety, security and survival. Is your property hurricane ready?
To view the Multimedia News Release, go to http://www.multivu.com/players/English/65822-state-farm-severe-weather-disaster-preparedness/
Clayton, one of the largest home builders in America, helped fulfill the dreams of an East Tennessee Children’s Hospital cancer patient by giving him the opportunity to design a Clayton home using CAD software commonly used at home building facilities.
Jake Clark, 16, became an honorary member of the Clayton team on Nov. 22 during a special ‘Team Jake’ celebration event at a home building facility in Bean Station, Tenn. His interests in construction projects with his dad, a home contractor, and his talents in drawing and 3D design made Jake the perfect fit to visit Clayton. While visiting the home building facility, the cancer survivor sat with a home designer and created a home model floor plan of his own, which was named “The Jake” in his honor.
To view the multimedia release go to:
https://www.multivu.com/players/English/80116510-clayton-honors-young-cancer-survivor/
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
Results from a large retrospective data analysis published in the American Journal of Transplantation (AJT) today, showed that liver transplantation patients who were treated early with Advagraf experienced a significantly increased graft survival benefit of 8% at 3 years post-transplant compared with patients treated with the current standard of care, tacrolimus immediate release (twice daily).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7451251-advagraf-prolonged-release-tacrolimus/
The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary non-profit dedicated to blood cancers, released 30 “proof points” - one for each day of September, Blood Cancer Awareness Month - to demonstrate its impact on the cancer landscape and progress towards a world without blood cancers.
LLS has invested more than $1 billion in research to advance breakthrough therapies and cures for blood cancer patients. In many cases, those treatments are now helping patients with other cancers and chronic diseases. Due to its focus on blood cancers, survival rates are improving. Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled and even quadrupled.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554851-lls-blood-cancer-awareness-month/
